What Does Recursion Pharmaceuticals (RXRX) Do? — Stock Outlook, Earnings, Market Cap, Related Stocks, Headquarters

Company overview

What Does Recursion Pharmaceuticals (RXRX) Do? — Stock Outlook, Earnings, Market Cap, Related Stocks, Headquarters

Updated June 10, 2026 · First published March 20, 2026

Recursion Pharmaceuticals (RXRX) is a US biotech company operating an AI-based drug discovery platform. Pipeline clinical progress, platform partnerships, funding, and market sentiment drive its revenue potential and stock price, and the stock attracts significant market interest regarding its outlook and related names.

🏢 What kind of company is Recursion Pharmaceuticals?

Recursion Pharmaceuticals (RXRX) is a US biotech company operating an AI-based drug discovery platform. By combining AI with automated biological experiments, the company runs a large-scale data-driven platform to identify and develop novel drug candidates, maintaining a pipeline spanning oncology, rare diseases, and other areas.

The core business is candidate discovery and development using its AI drug discovery platform. By combining AI, automated biological experiments, and large-scale data, the company rapidly identifies novel drug candidates and develops pipelines in oncology, rare diseases, and other areas, while expanding its platform through partnerships with large pharmaceutical and technology companies.

💰 How does Recursion Pharmaceuticals make money?

Business Segment	Revenue Weight	Description
Drug Pipeline	Core	Candidates in oncology, rare diseases, and other areas
Platform Partnerships	Key Growth Driver	Partnerships with large pharmaceutical and technology companies
AI Platform	Diversification Lever	AI-based drug discovery platform

The AI drug discovery platform and pipeline sit at the center of the business, with partnerships with large pharmaceutical and technology companies adding to the revenue base and validation. Pipeline clinical progress, platform partnerships, and candidate discovery efficiency are linked to corporate value. Because large-scale platform and R&D investments are made upfront, clinical and platform milestones and market sentiment weigh more on the stock than near-term operating results. Pipeline progress, platform partnerships, and funding will be the key drivers of corporate value going forward.

📐 Recursion Pharmaceuticals market cap and company scale

Market capitalization stands at $1.7B, and the company employs 600 people people.

As a growth-stage AI drug discovery biotech, the company highlights a differentiated platform combining AI with automated biological experiments, pipelines across multiple therapeutic areas, and large-scale partnerships as its competitive potential. It shares certain business characteristics with peers in the biotech space such as ABSI, RLAY, and NUVL, while pursuing differentiation through a large-scale, data-driven drug discovery platform. Since the company is pre-commercialization, resources are concentrated on platform and pipeline development.

📈 Recursion Pharmaceuticals outlook and share price trends

1-Year Price Performance

Analyst Consensus

2.1

Sell Hold Strong Buy

Target Price $7 +128.5% Current $3

52-Week Price Range

Low $3 High $7

vs. low +14.08% vs. high -55.99%

AI drug discovery efficiency, pipeline clinical progress, and the expansion of platform partnerships are the key medium- to long-term variables. AI-driven drug discovery efficiency and large-scale data assets form the basis of differentiation, while partnerships with large pharmaceutical and technology companies add validation and capital. In the near term, pipeline clinical outcome uncertainty, platform value validation, heavy investment burden, funding and dilution, competition, and market sentiment-driven share price volatility can act as factors driving stock price swings.

AI drug discovery efficiency and data assets
Pipeline clinical progress
Expanded partnerships with large pharmaceutical and technology companies

⚔️ Recursion Pharmaceuticals core strengths and risks

A differentiated drug discovery platform combining AI with automated experiments, pipelines across multiple therapeutic areas, and large-scale partnerships are its strengths, while pipeline and platform validation uncertainty, investment burden, and high share price volatility are the core risks.

💪 Core Strengths

AI Platform

Operates a large-scale, data-driven drug discovery platform combining AI with automated biological experiments.

Pipeline

Pipelines across oncology, rare diseases, and other areas reduce dependence on any single asset.

Large-Scale Partnerships

Partnerships with large pharmaceutical and technology companies secure platform validation and capital.

⚠️ Core Risks

Pipeline & Platform Validation

Significant uncertainty surrounds pipeline clinical outcomes and platform value validation.

Investment & Funding Burden

Exposed to large-scale platform and R&D investments, additional funding needs, and share dilution risk.

High Share Price Volatility

As a growth-stage company, the stock price is driven more by market sentiment than by operating results, resulting in very high volatility.

Recursion Pharmaceuticals competitors and related beneficiary stocks

Direct competitors grouped within the same biotech space include ABSI in AI-driven antibody discovery, RLAY in precision oncology drugs, and NUVL in targeted oncology therapeutics. Related names include SDGR in computational drug discovery, NVDA in AI acceleration chips, and BMY, a large pharmaceutical company with an oncology pipeline. Trends in AI drug discovery and the biotech industry are structurally linked to RXRX's business environment.

Competitors

Ticker	Company	Price	Change	Market Cap	P/E	PBR	ROE	Dividend Yield
ABSI	Absci Corp	$8.24	-4.7%	$1.4B	-	5.7	-57.72%	-
RLAY	Relay Therapeutics Inc	$18.89	+1.2%	$4.1B	-	4.6	-36.77%	-

Related stocks (beneficiaries)

Ticker	Company	Price	Change	Market Cap	P/E	PBR	ROE	Dividend Yield
SDGR	Schrodinger Inc	$18.80	-2.1%	$1.4B	-	4.3	-16.18%	-
NVDA	NVIDIA Corp	$218.36	-2.4%	$5.26T	27.6	23.0	117.21%	0.34%
BMY	Bristol-Myers Squibb Co	$63.75	-1.0%	$130.2B	14.0	5.8	46.7%	3.67%

Checkpoint	What to Verify	Current Status
AI Platform	AI drug discovery efficiency and data assets	Growth trajectory
Pipeline	Clinical progress of oncology and rare disease pipelines	Development in progress
Platform Partnerships	Expansion of partnerships with large pharmaceutical and technology companies	To be monitored
Volatility	Share price volatility driven by market sentiment	High volatility